Clearmind Medicine Inc December 2025 Form 6-K Analysis & Nasdaq Compliance

Based on my comprehensive analysis of available data, I need to clarify a significant finding regarding Clearmind Medicine Inc’s Form 6-K filings in December 2025.

While you specifically asked about a December 16th Form 6-K filing, my search reveals that Clearmind Medicine Inc’s most recent significant Form 6-K was actually filed on

, not December 16th. No evidence exists of a December 16th filing from the company in my search results[1][2][3].

The December 5, 2025 Form 6-K contained material information regarding regaining compliance with Nasdaq Listing Rule 5550(b)(1), the Minimum Stockholders’ Equity Rule[1][2][3].

• Compliance Status
  : Confirmed meeting the minimum $2,500,000 stockholders’ equity requirement[1][2]
• Nasdaq Notification
  : The company received formal notification on December 10, 2025, confirming compliance based on this Form 6-K filing[1][2][3]
• Ongoing Monitoring
  : Nasdaq indicated continued monitoring of the company’s compliance status[1][2]

• Stock Price
  : $2.72 as of December 16, 2025[0]
• Daily Performance
  : -8.48% decline[0]
• Market Cap
  : $14.86M[0]
• 52-Week Range
  : $2.42 - $87.20[0]

1. Listing Security
   : Nasdaq compliance eliminates delisting risk, providing stability for institutional investors[1][2][3]
2. Financial Health
   : Meeting equity requirements suggests improved capital structure[2]
3. Recent Performance
   : Despite today’s decline, the stock shows significant gains:
   • 1 Month: +853.72%[0]
   • 6 Months: +212.64%[0]
   • YTD: +87.59%[0]

1. Bid Price Compliance
   : The company still has until June 2, 2026, to address bid price deficiencies[3]
2. Continued Monitoring
   : Nasdaq’s ongoing oversight suggests continued scrutiny[1][2]
3. Volatility
   : The stock’s extreme 52-week range ($2.42-$87.20) indicates high volatility[0]

Clearmind Medicine Inc is a clinical-stage biotechnology company focused on developing psychedelic-derived therapeutics for major under-treated health problems, including alcohol use disorder[1][2]. The company trades on both Nasdaq (CMND) and Frankfurt Stock Exchange (CWY0)[1][2].

: The Nasdaq compliance announcement likely provided positive momentum, though the stock’s 8.48% decline on December 16th suggests mixed investor reaction[0].

:

• Positive
  : Eliminated delisting risk, improved financial position
• Concerns
  : Still operating with negative EPS (-$30.00)[0], need to achieve bid price compliance
• Valuation Metrics
  : P/B ratio of 5.95x suggests premium valuation relative to book value[0]

[1] Stock Titan - “Clearmind Medicine Successfully Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity” (https://www.stocktitan.net/news/CMND/clearmind-medicine-successfully-regains-compliance-with-nasdaq-s-2qptd7q9xvlm.html)
[2] Quiver Quant - “Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Rule on Minimum Stockholders’ Equity” (https://www.quiverquant.com/news/Clearmind+Medicine+Inc.+Regains+Compliance+with+Nasdaq+Listing+Rule+on+Minimum+Stockholders’+Equity)
[3] Investing.com - “Clearmind regains compliance with Nasdaq minimum equity rule” (https://www.investing.com/news/company-news/clearmind-regains-compliance-with-nasdaq-minimum-equity-rule-93CH-4405488)
[0] 金灵API Data